ライフサイエンスコーパス: activating factor

1 in (SM) to ceramide and inactivates platelet activating factor.

2 a ribosomal protein functioning as an ATPase-activating factor.

3 s, which are possible precursors of platelet activating factor.

4 ls, and the mediators histamine and platelet-activating factor.

5 ole blood and dampened responses to platelet-activating factor.

6 g of this response by TNF-alpha and platelet-activating factor.

7 d by administration of histamine or platelet-activating factor.

8 ted with liver inflammation and serum B cell-activating factor.

9 as also reversed by the addition of platelet-activating factor.

10 herapy with belimumab, an antibody to B-cell activating factor.

11 y, pneumolysin serves as a potent neutrophil activating factor.

12 een ezrin and F-actin as a function of these activating factors.

13 elevated levels of pro-inflammatory platelet-activating factors.

14 aling and biological actions of specific RTK-activating factors.

15 induction of mesoendodermal fates by Smad2/3-activating factors.

16 The apoptotic protease-activating factor 1 (Apaf-1) controls the onset of many

17 ding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C varepsilo

18 is, including apoptosome apoptotic peptidase activating factor 1 (APAF-1).

19 vage pathway dehydratase, apoptotic protease activating factor 1 (APAF1)-interacting protein (APIP),

20 associated with elevated apoptotic protease-activating factor 1 and a higher ratio of Bax/Bcl-2.

21 or without shRNA against apoptotic protease-activating factor-1 (Apaf-1).

22 ssion or the depletion of apoptotic protease-activating factor-1 (Apaf-1).

23 binding adaptor shared by apoptotic protease-activating factor-1, plant resistance proteins, and CED-

24 ontrast to apoptosis, not apoptotic protease activating factor-1.

25 ury via activation of receptors for platelet-activating factor, a proinflammatory signaling molecule

26 tively truncated phospholipids, and platelet-activating factor, a remarkably potent and pleiotropic i

27 Low platelet activating factor acetyl hydrolase activity was associat

28 mor necrosis factor receptor I, and platelet activating factor acetyl hydrolase.

29 We report that platelet-activating factor acetylhydrolase (PAFAH) Ib, comprised

30 e cytoplasmic PLA(2) enzyme complex platelet-activating factor acetylhydrolase (PAFAH) Ib, which cons

31 ilk containing diminished levels of platelet-activating factor acetylhydrolase (PAFAH).

32 Platelet-activating factor acetylhydrolase (PLA2G7) is a potent p

33 uch as alpha-N-catenin (CTNNA2) and platelet-activating factor acetylhydrolase 1b regulatory subunit

34 Platelet-activating factor acetylhydrolase 1B1 (LIS1), a critical

35 y ectopic expression of PL-specific platelet-activating factor acetylhydrolase 2 (PAFAH2) markedly re

36 ), and antioxidant enzyme activity (platelet-activating factor acetylhydrolase [PAF-AH] and superoxid

37 y, such as suggesting that baseline platelet-activating factor acetylhydrolase activity levels are re

38 Measurement of platelet-activating factor acetylhydrolase activity represents a

39 most potent effect was observed for platelet activating factor acetylhydrolase alpha (Paf-AHalpha), a

40 utations in the human gene encoding platelet-activating factor acetylhydrolase IB subunit alpha (Pafa

41 this study was to determine whether platelet-activating factor acetylhydrolase Sse and streptolysin S

42 y enzymatic assays for SpeB and the platelet-activating factor acetylhydrolase Sse, and a new type of

43 ChE and a new extracellular form of platelet-activating factor acetylhydrolase, PAFAH1b2.

44 Lp-PLA2, also known as platelet-activating factor acetylhydrolase, rapidly cleaves oxidi

45 In vivo and in vitro histamine and platelet-activating factor administration increases Fn14 receptor

46 ation of ectopic lymphoid structures (B-cell activating factor and B cell-attracting chemokine 1).

47 activated and primed for survival via B-cell activating factor and B-cell receptor-associated pathway

48 phosphorylation, homodimerization into gamma-activating factor and heterotrimerization into ISGF-3, b

49 As platelet-activating factor and HPC share structural semblances an

50 systemic inflammation with increased B cell-activating factor and IFN levels and induction of an IFN

51 abrogation of tolerance, no increased B cell-activating factor and IFN, and no IFN signature.

52 l counts, B-cell subset distribution, B cell-activating factor and immunoglobulin levels, and autoant

53 Interestingly, the activation of gamma-activating factor and ISGF3 was impaired only at early t

54 ary glands and abnormal expression of B cell-activating factor and its receptors.

55 The emergence of B-cell-activating factor and its related family members as crit

56 laxis suggest an important role for platelet-activating factor and its relationship to the need for p

57 l cell line induced upregulation of platelet activating factor and the fibrotic marker TGF-beta.

58 Previous studies highlighted the role of activating factors and epigenetic modifications in regul

59 well as B-cell survival factor BAFF (B-cell activating factor) and antiapoptotic molecule Bcl-2 leve

60 orating the molecular adjuvants BAFF (B cell activating factor) and APRIL (a proliferation-inducing l

61 ors for chemokines, PGs, histamine, platelet activating factor, and anaphylatoxin.

62 on, splenic plasma cells, circulating B cell activating factor, and intragraft transcripts for major

63 cluding sphingosine, sphingomyelin, platelet-activating factor, and lysophosphatidylcholine.

64 Lysophosphatidylcholine, lyso-platelet-activating factor, and several phospholipid fatty acids

65 However, clear mast cell-activating factors are not always apparent.

66 We identified B-cell-activating factor as a protein that promoted B-cell hype

67 Activation of the type I interferon/B cell-activating factor axis in SS has recently attracted part

68 At 2 years from transplantation, the B-cell activating factor/B-cell ratio was significantly higher

69 RABV-based vaccine expressing murine B cell activating factor (BAFF) (rRABV-mBAFF).

70 and B cell tropic factors, including B cell-activating factor (BAFF) and a proliferation-inducing li

71 gG-PB differentiation is dependent on B cell-activating factor (BAFF) and IL-10, whereas IgA-PB diffe

72 B-cell-activating factor (BAFF) and its receptor BAFF-R are imp

73 The cytokine B cell activating factor (BAFF) and its receptor, BAFF receptor

74 receptor editing and increased serum B cell-activating factor (BAFF) concentrations.

75 y evaluated B-cell subpopulations and B-cell activating factor (BAFF) in 136 patients (46 BOS, 41 no

76 We measured serum B-cell activating factor (BAFF) in 46 cGVHD patients receiving

77 The B cell activating factor (BAFF) inhibitor, belimumab, is the fi

78 B cell activating factor (BAFF) is a crucial survival factor fo

79 B-cell activating factor (BAFF) is an important cytokine for B-

80 B-cell-activating factor (BAFF) is associated with donor-specif

81 The B cell-activating factor (BAFF) is critical for B cell developm

82 B cell activating factor (BAFF) is essential for B cells to dev

83 th cGVHD have significantly increased B cell-activating factor (BAFF) levels and that their B cells a

84 nce of alloantibodies and high plasma B cell-activating factor (BAFF) levels in patients with cGVHD s

85 Sustained increase in B-cell-activating factor (BAFF) mRNA in the CNS and BAFF recept

86 result, mutant TWEAK associated with B-cell-activating factor (BAFF) protein and down-regulated the

87 -) B cells express elevated levels of B-cell-activating factor (BAFF) receptor (BAFF-R) and as a resu

88 dent survival signals provided by the B cell-activating factor (BAFF) receptor (BAFF-R).

89 , as well as a defect in BCR-mediated B-cell-activating factor (BAFF) receptor up-regulation and subs

90 oth the B cell receptor (BCR) and the B cell-activating factor (BAFF) receptor.

91 n of signals received through BCR and B cell activating factor (BAFF) receptor.

92 B-cell activating factor (BAFF) single nucleotide polymorphisms

93 B cell activating factor (BAFF) stimulation of the BAFF recepto

94 evated IgG autoantibody reactivity to B cell-activating factor (BAFF) was associated with SLE compare

95 d autoantibodies directed against the B cell-activating factor (BAFF) were associated with greater di

96 e approval of belimumab (which blocks B cell-activating factor (BAFF)) for use in patients with lupus

97 B-cell activating factor (BAFF), a member of the TNF family, is

98 cidin, interleukin 1 (IL-1), IL-4 and B cell-activating factor (BAFF), after IgD crosslinking.

99 gand (sRANKL), osteoprotegerin (OPG), B-cell activating factor (BAFF), and a proliferation-inducing l

100 roliferation-inducing ligand (APRIL), B-cell activating factor (BAFF), interleukin (IL)-6, and IL-8 i

101 IL (a proliferation-inducing ligand), B-cell activating factor (BAFF), tumor necrosis factor-alpha (T

102 encoding the cytokine and drug target B-cell activating factor (BAFF), was associated with multiple s

103 iferation-inducing ligand (APRIL) and B-cell-activating factor (BAFF), whereas removal of terminal si

104 eptor (BAFFR) expression and inhibits B-cell activating factor (BAFF)-induced B-cell survival in a ce

105 The B-cell-activating factor (BAFF)-receptor (BAFF-R) is restricted

106 dysfunctions, and one of these is the B cell-activating factor (BAFF).

107 mirroring deficiency of the cytokine B cell-activating factor (BAFF).

108 lator (BLyS), also referred to as the B-cell activating factor (BAFF).

109 proliferate to the prosurvival factor B cell activating factor (BAFF).

110 included Tnfsf13b, which encodes the B-cell activating factor (BAFF).

111 lonal antibody targeting the cytokine B cell-activating factor (BAFF).

112 Elevated B-cell-activating factor (BAFF; TNFSF13B) levels have been foun

113 with mice transgenic (Tg) for CD257 (B-cell activating factor, BAFF) developed CD5(+) B-cell leukemi

114 luence Mvarphi phenotype by mediating B cell-activating factor belonging to the TNF family (BAFF) and

115 The effects of B cell-activating factor belonging to the TNF family (BAFF) on

116 ity, NF-kappaB activation through the B cell-activating factor belonging to the TNF family (BAFF) rec

117 released the B-cell survival factor, B-cell activating factor belonging to the TNF family (BAFF), su

118 esistant to the survival factor BAFF (B cell-activating factor belonging to the TNF family).

119 B-cell activating factor belonging to the tumor necrosis factor

120 BAFF (B cell-activating factor belonging to the tumor necrosis factor

121 and be required for the release of the IGFR-activating factor, beta-arrestins were found to act down

122 sses some of the pertinent aspects of B-cell-activating factor biology and considers how recent advan

123 PAWP) fulfils the criteria set for an oocyte-activating factor by inducing oocyte activation and bein

124 ing is elicited by the delivery of an oocyte-activating factor by the sperm.

125 n signals, surfactant protein A and platelet-activating factor, by the developing mouse fetal lung (M

126 lobulins (IgG, IgA), cytokines with platelet activating factor, calcium ionophore, or phorbol myrista

127 We identified IL-18 as a TRAF6-activating factor capable of enhancing lymphopenia-induc

128 inophils to chemoattractants (FMLP, platelet-activating factor, CCL11, CCL5, CXCL8) with respect to d

129 from spontaneous apoptosis induced by B cell-activating factors CD40L, TNF-alpha, and fibronectin.

130 SHU1, and UAF30, a component of the upstream activating factor complex (UAF), which regulates rDNA tr

131 Total airway IgE correlated with B-cell activating factor concentrations.

132 and depends on the presence of an additional activating factor (e.g. the dipeptide benzyloxycarbonyl-

133 r and activator of transcription 3 (survival activating factor enhancement [SAFE] pathway) in the are

134 perfusion injury salvage kinase and survivor activating factor enhancement pathways in the infarct bo

135 perfusion injury salvage kinase and survivor activating factor enhancement pathways were similarly up

136 perfusion injury salvage kinase and survivor activating factor enhancement pathways, improved systoli

137 perfusion injury salvage kinase and survivor activating factor enhancement pathways.

138 The HIF-inducible myeloid-activating factors erythropoietin, stem cell factor (SCF

139 ence relieved B cells of the need for B cell activating factor for survival.

140 and rendering B cells independent of B cell activating factor for survival.

141 ately consisted of potent chemotactic and/or activating factors for phagocytes, including interleukin

142 DA was purified as a SAR-activating factor from vascular sap of Arabidopsis thali

143 Although ILC2-activating factors have been identified, the mechanisms

144 show here that VirA's receiver domain is an activating factor if virG is expressed from its native p

145 kinases, whereas it is independent of B-cell activating factor, IFN, and Toll-like receptor signaling

146 together, our results define G-CSF as a CSC-activating factor in neuroblastoma, suggest a comprehens

147 t phospholipids and biosynthesis of platelet-activating factor in noninflammatory remodeling pathway.

148 By neutralizing B cell-activating factor in vivo, we found an arrest in periphe

149 d cells reduced the expression of fibroblast-activating factors in tumor-associated macrophages resul

150 hase kinase 3beta inhibitor, blocks platelet activating factor-induced activation of glycogen synthas

151 In ADSA lymphoblasts, platelet-activating factor-induced Ca(2+) mobilization was signif

152 manner, LXs significantly inhibited platelet-activating factor-induced increases in leukocyte-platele

153 fter B-cell receptor stimulation, and B-cell activating factor-induced nuclear factor kappaB2/p52 gen

154 Following platelet-activating factor-induced shock, MK886 increased surviva

155 ocking antibody prevented histamine/platelet-activating factor-induced vascular subcutaneous permeabi

156 receptor alpha (sIL-2Ralpha), sCD27, B-cell activating factor, interferon gamma-induced protein 10 (

157 okines (insulin-like growth factor-1, B-cell activating factor, interleukin-6, interleukin-10).

158 ncement factor, and CpG ODN, serving as a DC activating factor, into sponge-like macroporous cryogels

159 YY1 is thus the first autosomal activating factor involved in a fundamental and conserve

160 ET formation after stimulation with platelet activating factor, ionomycin, or phorbol 12-myristate 13

161 LRC4 (interleukin-converting enzyme protease-activating factor [IPAF]) responds to the cytosolic pres

162 d be reactivated by intracellular telomerase-activating factors (iTAFs) from multiple cell types.

163 yme (FXIa) that contributes to hemostasis by activating factor IX.

164 st double-stranded DNA, and increased B cell-activating factor levels.

165 uced despite slightly increased serum B cell-activating factor levels.

166 CD21(low) B cells and a reduction in B cell-activating factor levels.

167 herapies targeting the IFN family and T-cell-activating factors may therefore be of benefit in a subs

168 -related protein 1 (P < .001) and osteoclast-activating factor MIP-1alpha (P < .05) also were signifi

169 oledronic acid, anti-DKK-1 MoAb, anti-B-cell activating factor MoAb and bortezomib, Btk inhibitor) sh

170 esting that SOX30 is a novel transcriptional activating factor of p53.

171 Mice overexpressing B cell activating factor of the TNF family (BAFF) develop syste

172 B cell activating factor of the TNF family (BAFF), also known a

173 APRIL and the closely related ligand, B-cell activating factor of the TNF family (BAFF), bind these l

174 The B-cell activating factor of the TNF family (BAFF), nucleic acid

175 o associated with increased levels of B cell-activating factor of the TNF family (BAFF; also known as

176 DC-produced survival factors such as B cell-activating factor of the TNF family and a proliferation-

177 The B cell-activating factor of the TNF family receptor (BAFF-R), e

178 n are completely independent of BAFF (B cell-activating factor of the TNF family) or APRIL (a prolife

179 The ASC survival factors B cell-activating factor of the tumor necrosis factor (TNF) fam

180 B cell activating factor of the tumor necrosis factor family (B

181 e effects of rituximab (anti-CD20) on B-cell-activating factor of the tumor necrosis factor family (B

182 B cell-activating factor of tumor necrosis factor family (BAFF)

183 Although many trans-activating factors of VEGF have been described, the tran

184 To analyze the influence of these activating factors on the organization of ezrin on lipid

185 tor of microglia) and fractalkine (microglia-activating factor) on visceral hyperalgesia in rats with

186 contribute to gene regulation by recruiting activating factors or remodelling nucleosomes.

187 emoattractants, such as chemokines, platelet-activating factor, or FMLP, through a process known as p

188 1 (APE1) and stalling on the fold to recruit activating factors, or OGG1 binds OG and facilitates act

189 Platelet-activating factor (PAF [1-O-alkyl-2-acetyl-sn-glycero-3-

190 The platelet activating factor (PAF) acetyl hydrolase 1b (Pafah1b) co

191 The platelet-activating factor (PAF) acetylhydrolase SsE produced by

192 1B2 and PAFAH1B3 subunits of type I platelet-activating factor (PAF) acetylhydrolase, a phospholipase

193 UV-induced keratinocyte-derived platelet-activating factor (PAF) activates mast cell migration, i

194 ycerophosphocholines (Ox-GPCs) with platelet-activating factor (PAF) activity produced non-enzymatica

195 chained phospholipids--inflammatory platelet-activating factor (PAF) and apoptotic oxidatively trunca

196 e hydrolytic inactivation of plasma platelet activating factor (PAF) and is also known as PAF acetylh

197 Platelet activating factor (PAF) and PAF-like lipids induce infla

198 nd photoimmune suppression, such as platelet-activating factor (PAF) and serotonin (5-HT) receptor an

199 f the yoghurts PL fractions against platelet-activating factor (PAF) and thrombin-induced platelet ag

200 ver the past few years, the role of platelet-activating factor (PAF) as a potent mediator involved in

201 We used platelet-activating factor (PAF) as a proinflammatory agonist.

202 s resveratrol and quercetin, on the platelet activating factor (PAF) biosynthetic enzymes, acetyl-CoA

203 Platelet-activating factor (PAF) causes wheal and flare responses

204 tte smoking leads to an increase in platelet-activating factor (PAF) content and PAF receptor express

205 ate surfactant protein-A (SP-A) and platelet-activating factor (PAF) expression, which increases in t

206 have implicated the lipid mediator platelet-activating factor (PAF) in UVB-mediated systemic immunos

207 f LE that the phospholipid mediator platelet-activating factor (PAF) increases in LE and that PAF rec

208 Platelet-activating factor (PAF) increases permeability to macrom

209 Platelet-activating factor (PAF) is a mediator of inflammation sh

210 Platelet-activating factor (PAF) is a naturally occurring phospho

211 Platelet-activating factor (PAF) is a phospholipid mediator with

212 Platelet-activating factor (PAF) is a potent lipid mediator that

213 Platelet-activating factor (PAF) is a potent phospholipid-derived

214 Platelet-activating factor (PAF) is a powerful proinflammatory me

215 Platelet-activating factor (PAF) is an important mediator and cor

216 The phospholipid platelet-activating factor (PAF) is an important mediator of infl

217 nflammation are not identified, but platelet-activating factor (PAF) is implicated as a potential rat

218 Platelet-activating factor (PAF) mediates an array of biological

219 Animal and human data show that platelet-activating factor (PAF) mediates the life-threatening ma

220 fter anaphylaxis, administration of platelet-activating factor (PAF) or histamine, and exposure to re

221 n-2 siRNA showed enhanced basal and platelet-activating factor (PAF) or lipopolysaccharide-stimulated

222 AA and PGE2 release, accompanied by platelet-activating factor (PAF) production.

223 hat antagonists of 5-HT(2A) and the platelet-activating factor (PAF) receptor can block cis-UCA-induc

224 llular Leishmania, we surmised that platelet-activating factor (PAF) receptor had a significant role

225 synonym KC) or the lipid mediator platetelet-activating factor (PAF) was only partially reduced.

226 proinflammatory glycerophospholipid platelet-activating factor (PAF) were markedly reduced in SRC-1/-

227 oiting molecular mimicry to degrade platelet-activating factor (PAF), a host-derived inflammatory pho

228 and BLP stimulated the synthesis of platelet activating factor (PAF), a potent lipid mediator, in hum

229 The phospholipid, platelet-activating factor (PAF), exerts multiple physiological f

230 at the lipid inflammatory mediator, platelet-activating factor (PAF), synthesized by activated neutro

231 hibits hyperpermeability induced by platelet-activating factor (PAF), VEGF in ECV-CD8eNOSGFP (ECV-304

232 ophil activation in the presence of platelet activating factor (PAF).

233 neutrophil recruitment by targeting platelet-activating factor (PAF).

234 sophosphatidylcholine (lysoPCh) and platelet activating factor (PAF).

235 of prostaglandin I(2) (PGI(2)) and platelet-activating factor (PAF).

236 the lipid mediator of inflammation, platelet-activating factor (PAF).

237 s, including adhesion molecules and platelet-activating factor (PAF).

238 he production of the lipid mediator platelet-activating factor (PAF).

239 G(+)); and (5) both TNFRSF17 mRNA and B cell-activating factor protein were up-regulated.

240 Signaling from the BCR and B cell activating factor receptor (BAFF-R or BR3) differentiall

241 sensitive to trophic factors, such as B cell-activating factor receptor (BAFF-R or BR3) during develo

242 was more dominantly controlled by the B-cell-activating factor receptor (BAFF-R), a gene that is link

243 that PTP1B negatively regulates CD40, B cell activating factor receptor (BAFF-R), and TLR4 signaling

244 Rather, high CD45 expression reduces B-cell activating factor receptor (BAFFR) expression and inhibi

245 ty to generate oxidized lipids with platelet-activating factor receptor (PAF-R) agonist activity.

246 ting oxidized lipid agonists of the platelet-activating factor receptor (PAF-R).

247 anoma metastasis, via activation of platelet-activating factor receptor (PAFR) and cAMP-responsive el

248 was blocked using a monoclonal anti-platelet activating factor receptor (PafR) antibody and Ginkgolid

249 We have previously shown that the Platelet-Activating Factor Receptor (PAFR) engagement in murine m

250 Here, we examined the role of platelet activating factor receptor (PAFR) in colitis-associated

251 identified a prominent role for the platelet-activating factor receptor (PAFr) in hypoxia-associated

252 Platelet-activating factor receptor (PAFR) is a G protein-coupled

253 c activity in a manner dependent on platelet-activating factor receptor (PAFR) signaling.

254 immunoglobulin receptor (pIgR) and platelet-activating factor receptor (PAFr) to attach and invade c

255 n interleukin 1alpha (IL-1alpha) or platelet-activating factor receptor (PAFR), an important host rec

256 umannii binds to A549 cells through platelet-activating factor receptor (PAFR), resulting in activati

257 Moreover, expression of platelet-activating factor receptor (PAFR), which is known to pot

258 n immune responses include CD36 and platelet-activating factor receptor (PAFR).

259 cells is mediated by host-expressed platelet-activating factor receptor (PAFR).

260 cooperative signaling through BCR and B cell-activating factor receptor 3 (BR3).

261 ceptors and excluded key candidates platelet-activating factor receptor and CCR5.

262 ivation lowered surface BCR, CD19 and B cell-activating factor receptor and increased expression of p

263 ts revealed that L5 signals through platelet-activating factor receptor and lectin-like oxidized LDL

264 Platelet-activating factor receptor blockade protected synapses i

265 uction, proliferation of T cells, and B cell-activating factor receptor expression on B cells.

266 ect resulted in part from decreased platelet-activating factor receptor expression on endothelia and

267 or therapeutic agents that modulate platelet-activating factor receptor expression, may confer protec

268 Anaphylaxis was inhibited by platelet-activating factor receptor or histamine receptor 1 block

269 olvement for an unrelated GPCR (the platelet-activating factor receptor), indicating that it may be a

270 2, we show evidence for enhanced BCR, B cell-activating factor receptor, and CD40 coreceptor programs

271 r-1, protease activated receptor-3, platelet activating factor receptor, and factor V.

272 of B-cell activation molecules CD69, B-cell-activating factor receptor, and transmembrane activator

273 d IL-15 production in B cells through B cell-activating factor receptor, whereas IL-15, a potent grow

274 nctional itBreg cells in a CD40L- and B cell-activating factor receptor-dependent manner.

275 sidues on pneumococcal cell wall to platelet-activating factor receptor.

276 tor, or cell wall phosphorylcholine/platelet-activating factor receptor.

277 proteins suggests roles in recruiting and/or activating factors required to fill such gaps.

278 High-level soluble B-cell activating factor (sBAFF) was observed in kidney recipie

279 firing rate is directly determined by trans-activating factor search times.

280 onducted a biochemical screen for macrophage-activating factors secreted by metastatic carcinomas.

281 ound that histamine, serotonin, and platelet-activating factor, small molecule vascular permeabilizin

282 ophage, and neutrophil secretion of platelet-activating factor subsequent to FcgammaR stimulation by

283 expression of the autoregulatory viral trans-activating factor Tat is reduced to subthreshold levels.

284 The recruited neutrophils secreted a B cell-activating factor that highly accelerated plasma cell ge

285 letion of basophils and blockade of platelet-activating factor, the key components of the IgG1 pathwa

286 The approval of anti-B cell activating factor therapy and an increasing body of open

287 s responded to AgR stimulation and to B cell activating factor, they displayed decreased survival and

288 r, memory CD8(+) T cells that release the DC-activating factor TNF-alpha before the release of cytoto

289 ansferase activity of YopJ and identify this activating factor to be inositol hexakisphosphate (IP(6)

290 re used together with cytoplasmic Ran GTPase-activating factors to demonstrate that importin-alpha/CA

291 ediators, matrix metalloproteinase-9, B-cell activating factor, transforming growth factor-beta1, and

292 or normal B cells with CD40-ligand or B-cell-activating factor upregulated miR-155 and enhanced sensi

293 ines (CXCL13, CCL19, CCL21, CCL1, and B-cell-activating factor) was increased in pancreatic and serum

294 Lysophosphatidylcholine and lyso-platelet-activating factor were also associated directly with ins

295 Most of the complement-activating factors were upregulated, whereas the complem

296 tryptamine), platelet factor 4, and platelet-activating factor, which specifically stimulated differe

297 as a proliferation-inducing ligand or B cell-activating factor, which were constitutively expressed a

298 PAR-1 and its activating factors, which are expressed on tumor cells a

299 The venom is now known to act by directly activating factor X, and a form of the clotting test is

300 actor/selenocysteine tRNA gene transcription activating factor/zinc finger protein 143 (SBF/Staf/ZNF1